

MÖLNLYCKE HEALTHCARE US TO CO-PROMOTE ENDOFORM™ IN THE U.S.

Highlights

- AROA has entered into an exclusive agreement with Mölnlycke to co-promote Endoform in the United States.
- The arrangement will expand access to AROA ECM technology while allowing AROA's direct sales team to focus on strategic priorities.
- AROA retains ownership of Endoform and will continue to manufacture, distribute, and supply the product.
- FY27 financial guidance remains unchanged.

Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company') is pleased to announce it has established an exclusive agreement with Mölnlycke Healthcare US for co-promotion of Endoform in the United States, effective 16 October 2026.

The arrangement combines Endoform and AROA's proprietary AROA ECM™ technology with Mölnlycke's established market leading position and commercial reach. It is intended to expand access to Endoform in the US post-acute setting and support the product's continued growth.

The agreement will also allow AROA to focus its resources on key strategic priorities, including growing Myriad's adoption in surgical settings and pursuing the current opportunity for Symphony in the outpatient setting.

The agreement relates solely to Endoform for post-acute settings in the United States market. AROA retains ownership of Endoform and AROA ECM technology and will continue to manufacture, distribute and supply Endoform.

AROA's other product portfolios and commercial arrangements, including Endoform distribution outside the United States, remain unchanged.

AROA's FY27 full year financial guidance, of NZ\$115-125 million total revenue and normalised EBITDA of \$8-11 million remains unchanged.¹

AROA Founder and CEO Brian Ward said:

"We welcome the opportunity to partner with Mölnlycke, a well-established advanced wound care business known for excellence. Mölnlycke's deep expertise in wound care and broad commercial footprint provide a strong platform to bring Endoform to more clinicians and patients.

¹Normalised EBITDA is non-conforming financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and assess the Group's comparative financial performance without distortion from one-off transactions. The impact of non-cash share-based payments expense and unrealised foreign exchange gains or losses has also been removed. This approach is used by Management and the Board to assess the Group's comparative financial performance.



This arrangement also allows us to concentrate our efforts on AROA's strategic priorities - sustaining Myriad's growth and pursuing the significant opportunity for Symphony, while continuing to manufacture and supply Endoform."

Mölnlycke VP Americas, Craig Kennedy, said: "Improving wound care requires strong partnerships and continued innovation. Our collaboration with Aroa reflects a shared commitment to advancing clinical practice, supporting healthcare professionals, and improving patient outcomes. By adding Endoform to our advanced wound dressing portfolio, we're expanding the solutions available to clinicians and addressing the diverse need of the patients they serve."

About Endoform

Endoform products are unique extracellular matrix products, composed of AROA ECM, for the management of acute and chronic wounds in the outpatient or post-acute settings.

About Mölnlycke

Mölnlycke Health Care is a world-leading MedTech company specializing in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Patricia Industries, part of Investor AB, and is headquartered in Sweden. www.molnlycke.com

<ENDS>

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

Contact

investor@aroa.com

About AROA™
Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for everybody’.
We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach.
Over 7 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc.
Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com